Jade Biosciences, Inc.
NASDAQ:JBIOBiotechnology
-$0.21 today
- Market cap
- $1.07B
- Beta
- 1.45
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$2.24
Volume 0.79M
Average 0.83M
JBIO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Jade Biosciences, Inc.NASDAQ: JBIO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $36.05M, compared with $0 a year earlier. Trailing-twelve-month research & development was $109.15M. Over 3 fiscal years it compounded at +34.1% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $36.05M or moves back toward the trailing-twelve-month quarterly average of $27.29M.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 93.12M USD
- Year-over-year change
- +75.1%
- 4-year CAGR
- +57.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 93.12M | +75.1% |
| FY2024 | 2024-12-31 | 53.19M | -17.2% |
| FY2023 | 2023-12-31 | 64.22M | +66.3% |
| FY2022 | 2022-12-31 | 38.62M | +157.7% |
| FY2021 | 2021-12-31 | 14.99M | — |
Research & Development vs competitors
How JBIO compares with its peers on the latest reported figures
- JBIO's LTM Mar 2026 research & development of $109.15M is the 5th highest of the 9 companies compared; the peer median is $97.97M.
- Its year-over-year change of +200.2% is the 2nd highest of 9, against a peer median of +35.8%.
- Over three fiscal years its annual growth of +34.1% compares with a peer median of +45.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $261.87M | +51.3% | +45.5% | — | |
| LTM Mar 2026 | $220.82M | +62.1% | +69.0% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $139.61M | -8.4% | — | — |
| LTM Mar 2026 | $126.01M | -0.7% | +67.6% | — | |
| LTM Mar 2026 | $109.15M | +200.2% | +34.1% | — | |
| LTM Mar 2026 | $69.93M | +20.4% | +34.8% | — | |
| LTM Mar 2026 | $56.72M | +60.6% | -12.2% | 677.9% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $49.38M | +11.3% | +45.0% | — |
| LTM Mar 2026 | $22.1M | +292.9% | +39.4% | — | |
| Peer median (excluding JBIO) | $97.97M | +35.8% | +45.0% | 677.9% | |
Competitors are the stored peer set for JBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 15K | 68K | 96K | 282K | 0 |
| Gross Profit | (15K) | (68K) | (96K) | (282K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 14.99M | 38.62M | 64.22M | 53.19M | 93.12M |
| Selling, General & Admin | 8.02M | 14.55M | 17.09M | 21.13M | 20.42M |
| Operating Expenses | 23.01M | 53.17M | 81.31M | 74.31M | 113.54M |
| Depreciation & Amortization | 15K | 68K | 96K | 282K | 26K |
| EBITDA | (22.95M) | (51.42M) | (75.37M) | (69.29M) | (127.33M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (23.02M) | (53.24M) | (81.41M) | (74.6M) | (113.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 65K | 1.83M | 5.95M | 5.04M | 7.78M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 62K | 1.75M | 5.94M | 5.02M | (13.81M) |
| Income Before Tax | (22.96M) | (51.49M) | (75.47M) | (69.57M) | (127.35M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 3K | 25K | 56K | 55K | 58K |
| Net Income | (22.96M) | (51.51M) | (75.52M) | (69.63M) | (127.41M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (32.96) | (73.67) | (100.38) | (85.26) | (4.06) |
| EPS (Diluted) | (32.96) | (73.67) | (100.38) | (85.26) | (4.06) |
| Weighted Avg Shares | 697.44K | 699.2K | 752.33K | 816.63K | 31.36M |
| Weighted Avg Shares (Diluted) | 697.44K | 699.2K | 752.33K | 816.63K | 31.36M |
Jade Biosciences, Inc.
NASDAQ:JBIO
Intrinsic Alpha fair value
Locked
Current Price
$15.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.